In the context of AOSD, IL-6 plays a central role in driving systemic inflammation and anemia. In this case, the efficacy of tocilizumab, an IL-6 receptor inhibitor, underscores the critical contribution of IL-6 to the patient's inflammatory and hematologic abnormalities. Here, IL6 is linked to anemia.